MedTrace Logo

DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)

NCT06539182 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 155

Last updated 2025-12-01

No results posted yet for this study

Summary

This study will treat patients with CLL/SLL whose disease comes back or is not responding to prior therapy, or if they can not bear side effects of the prior treatment. This study will assess the anti-tumor activity of DZD8586 as monotherapy. It will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body.

Conditions

  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Interventions

DRUG

DZD8586

Daily oral dose of DZD8586 at 25 mg.

DRUG

DZD8586

Daily oral dose of DZD8586 at 50 mg.

DRUG

DZD8586

Daily oral dose of DZD8586 at 75 mg.

Sponsors & Collaborators

  • Dizal Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Jianyong Li · First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-29
Primary Completion
2027-09-30
Completion
2028-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06539182 on ClinicalTrials.gov